Novo Nordisk A/S (NVO) Covered Calls

Novo Nordisk A/S covered calls Novo Nordisk A/S is a leading global healthcare company specializing in diabetes and other serious chronic conditions, including obesity, rare blood disorders, and endocrine diseases. The company is a pioneer in GLP-1 therapy and insulin manufacturing, operating through two primary segments: Diabetes and Obesity care, and Rare Disease. With operations in nearly 80 countries, Novo Nordisk provides innovative therapies that reach millions of patients worldwide.

You can sell covered calls on Novo Nordisk A/S to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NVO (prices last updated Wed 4:16 PM ET):

Novo Nordisk A/S (NVO) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
47.19 -3.11 47.01 47.10 46.5M 14 347
Covered Calls For Novo Nordisk A/S (NVO)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 47 1.96 45.14 4.1% 88.0%
Mar 20 45 4.05 43.05 4.5% 36.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Core Business and Products

Novo Nordisk A/S (NVO) is a global leader in cardiometabolic health, holding a dominant position in the diabetes and obesity treatment markets. Entering February 2026, the company has transitioned from a supply-constrained growth phase into a diversified innovation cycle, led by the successful U.S. commercial launch of its first-of-its-kind obesity pill. The business is organized around high-value therapeutic categories:

  1. Diabetes and Obesity Care: This is the firm’s primary growth engine. It features the blockbuster semaglutide franchise, including Ozempic for type 2 diabetes and Wegovy for chronic weight management. In early 2026, the company launched the "Wegovy Pill," a daily oral GLP-1 that has seen rapid adoption (over 8,000 prescriptions weekly by mid-January) due to its convenience. Additionally, its "CagriSema" combination therapy is under active FDA review, promising superior weight loss and glycemic control.
  2. Rare Disease and Biopharm: Novo Nordisk maintains a strong portfolio in hemophilia and growth hormone disorders. In 2026, the company is leveraging its acquisition of Akero Therapeutics to expand into MASH (metabolic dysfunction-associated steatohepatitis), with Wegovy recently receiving a label expansion for this underserved indication.
  3. Insulin Leadership: As one of the world’s three major insulin producers, Novo Nordisk provides a stable foundation of recurring revenue. Its once-weekly insulin icodec has become the standard of care in several international markets, significantly reducing the treatment burden for patients.

Competitive Landscape

The pharmaceutical landscape in 2026 is defined by an intense "duopoly" battle in the $100 billion+ obesity market, as well as pressure from traditional large-cap peers:

  1. The Primary Rival: Eli Lilly and Company remains the most formidable competitor. Lilly’s Zepbound and Mounjaro (tirzepatide) compete directly with Wegovy and Ozempic. While Novo Nordisk currently leads the "oral" market, it faces the upcoming launch of Lilly’s rival pill, orforglipron.
  2. Cardiometabolic Competitors: In the broader diabetes and cardiovascular space, Novo Nordisk competes with AstraZeneca and Novartis. It also vies for MASH market share against specialized firms like Madrigal Pharmaceuticals.
  3. Institutional Peers: The company also monitors Pfizer and Sanofi, both of which are aggressively investing in next-generation weight-loss and insulin therapies to challenge the current market leaders.

Strategic Outlook and Innovation

As of February 2026, Novo Nordisk is under the leadership of new CEO Mike Doustdar, who is focused on rebuilding market trust and expanding patient access after the supply shocks of 2025. The company is investing tens of billions of DKK annually through 2026 to scale its manufacturing capacity, particularly in the U.S. and Europe. Innovation is centered on "Amycretin," a co-agonist targeting both GLP-1 and amylin receptors, which is currently in phase 3 development. Strategically, the company is navigating new U.S. pricing agreements that went into effect in January 2026, trading lower per-unit prices for significantly higher volume and expanded Medicare coverage. With a 2026 outlook focused on rebounding from 2025 headwinds and a robust pipeline in Alzheimer’s and liver disease, Novo Nordisk remains the primary architect of the modern obesity care revolution.